1. Home
  2. EDU vs CRSP Comparison

EDU vs CRSP Comparison

Compare EDU & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Oriental Education & Technology Group Inc.

EDU

New Oriental Education & Technology Group Inc.

HOLD

Current Price

$50.77

Market Cap

7.3B

Sector

Real Estate

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$47.27

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDU
CRSP
Founded
1993
2013
Country
China
Switzerland
Employees
84111
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
5.0B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
EDU
CRSP
Price
$50.77
$47.27
Analyst Decision
Strong Buy
Buy
Analyst Count
4
17
Target Price
$62.80
$70.29
AVG Volume (30 Days)
561.4K
1.6M
Earning Date
04-22-2026
05-11-2026
Dividend Yield
2.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
$12.83
$807.72
Revenue Next Year
$11.16
$172.52
P/E Ratio
$24.75
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$41.62
$44.12
52 Week High
$64.97
$78.48

Technical Indicators

Market Signals
Indicator
EDU
CRSP
Relative Strength Index (RSI) 65.02 38.48
Support Level $50.49 $45.52
Resistance Level $50.98 $60.10
Average True Range (ATR) 1.06 2.28
MACD 0.17 -0.62
Stochastic Oscillator 94.79 8.69

Price Performance

Historical Comparison
EDU
CRSP

About EDU New Oriental Education & Technology Group Inc.

New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: